Eli Lilly (LLY) has surged to the forefront of the U.S. weight loss drug market, capturing a commanding 60% market share, while rival Novo Nordisk’s share has fallen to 39%. This shift follows a comparative study showing superior weight loss outcomes with Lilly’s offerings, alongside significant investments in manufacturing to ensure product availability. Despite this success, competition remains fierce, particularly with Novo’s established oral Wegovy product.
Lilly’s weight loss portfolio, driven by the dual-action drugs Zepbound and Mounjaro, has generated over $11 billion in revenue in the last quarter alone, contributing to a 43% overall revenue increase to more than $19 billion. The recent approval of Foundayo, which can be taken with food, adds to Lilly’s competitive edge. However, the company’s future leadership may hinge on retatrutide, a promising candidate targeting three hormonal pathways, which has shown potential for superior efficacy in trials.
Investors should monitor Lilly’s ongoing trials for retatrutide, as its success could solidify the company’s dominance in the weight loss sector and enhance its long-term growth prospects.
Source: fool.com